Bilan Therapeutics is a biotechnology company developing immunotherapies designed to protect the liver from metastatic cancer.
THE CHALLENGE
Metastatic disease is responsible for most cancer deaths. The liver is among the most frequent sites where cancer cells from primary tumors establish metastatic tumors.
Current cancer treatments primarily target established disease. Bilan is developing a different strategy focused on making the liver less permissive to metastatic tumor formation.
CONTACT BILAN
We welcome inquiries from investors, scientific collaborators, clinical researchers, and development partners.
ABOUT
Bilan Therapeutics is a preclinical biotechnology company based in Massachusetts, United States. We are developing immunotherapies intended to protect the liver from metastatic cancer.
01
OUR MISSION
We believe that treating established metastatic tumors is not the only possible strategy. By changing the conditions that support metastatic tumor formation, it may be possible to intervene before clinically detectable tumors become established.
02
WHY WE FOCUS ON LIVER METASTASIS
Primary tumors can often be treated with surgery, radiation, systemic therapy, or combinations of these approaches. The clinical outlook changes substantially when cancer spreads to distant organs.
The liver is a frequent site of metastasis across several major cancers. Its specialized immune and vascular environments can support the survival and growth of disseminated cancer cells. Bilan is developing therapies intended to make the liver resistant to metastatic tumor formation.
FOUNDER
Founder and Chief Executive Officer
Dr. Steven Zanganeh is a cancer researcher whose work focuses on immunoengineering, immune regulation, and translational therapeutic development. He founded Bilan Therapeutics to translate his research into therapies that address metastatic disease through organ-focused immune intervention.
OUR APPROACH
Bilan is developing immunotherapies intended to shift the immune environment of the liver toward antitumor activity.
Rather than treating only established metastatic tumors, our approach is designed to interfere with the early biological processes that allow disseminated cancer cells to establish new tumors in the liver.
Bilan’s programs are being developed to produce several complementary antitumor effects:
Antitumor immune activity
Cancer-cell migration and invasion
Prometastatic tumor programs
Tumor angiogenesis
HepImm-1
HepImm-1 is Bilan’s lead preclinical liver-metastasis program.
HepImm-1 is designed to reprogram liver-resident immune cells and establish an antitumor environment that resists metastatic tumor formation in the liver.
The program is being evaluated as a potential treatment for patients who have completed curative-intent treatment but remain at elevated risk of developing liver metastases.
FUTURE PLATFORM EXPANSION
Bilan’s initial development work is focused on HepImm-1 and the liver. The company’s broader objective is to apply the same organ-protection principle to other sites commonly affected by metastatic cancer, including the lung.
CONTACT BILAN THERAPEUTICS
Bilan Therapeutics welcomes inquiries from investors, scientific collaborators, clinical researchers, and development partners.
SEND US A MESSAGE